Advances in Tuberculosis Diagnostics: The Xpert MTB/RIF Assay and Future Prospects for a Point-of-Care Test
The Patient-Reported Outcome (PRO) Consortium: A Collaborative Approach to PRO Instrument Development and Qualification
Development of a patient-reported outcome (PRO) instrument to assess complex activities of daily living and interpersonal functioning in patients with mild cognitive impairment due to suspected Alzheimer’s disease: the qualitative research phase
Opportunities and Challenges of Safety Biomarker Qualification: Perspectives from the Predictive Safety Testing Consortium
The advantages of frontotemporal degeneration drug development (Part 2 of frontotemporal degeneration: the next therapeutic frontier)
Global standardization measurement of cerebral spinal fluid for Alzheimer’s disease: an update from the Alzheimer’s Association Global Biomarkers Consortium
Critical Path Institute Names Martha Brumfield CEO The Board of Directors of the Critical Path Institute (C-Path) announced today that Martha Brumfield, Ph.D., has been named interi
CFAST Announces Parkinson’s Disease Drug Development Milestone: Release and Availability of a PD Therapeutic Area Data Standard
